Rafael Holdings, Inc.

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in other companies developing pharmaceuticals and medical devices. Its lead candidate is Trappsol® Cyclo™, currently in clinical trials for Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. The company's primary focus is the continued development of Trappsol® Cyclo™ through its ongoing pivotal Phase 3 clinical trial, potential regulatory approval, and commercialization. Rafael Holdings also holds a majority equity interest in LipoMedix Pharmaceuticals Ltd., a clinical-stage pharmaceutical company, and a majority interest in Cornerstone Pharmaceuticals, Inc., a cancer metabolism-based therapeutics company. Additionally, it has a majority interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments for minimally invasive surgeries, and a majority interest in Day Three Labs, Inc., which provides technology and innovation like Unlokt™ to third-party manufacturers. The company also owns Barer Institute Inc., a wholly-owned cancer research entity with substantially curtailed operations. Historically, Rafael Holdings owned real estate assets. As of July 31, 2025, its sole remaining real estate asset is a portion of a commercial building in Jerusalem, Israel. In May 2023, the company invested in Cyclo, a clinical-stage biotechnology company developing cyclodextrin-based products for neurodegenerative diseases, whose lead candidate is Trappsol® Cyclo™ for NPC1.